SPYGLASS PHARMA INC
SGPNASDAQ๐ #2286 by market capEarnings Mar 25US Equity
โโ
Quote unavailableTrack SGP
Get earnings, price moves & breaking news on Telegram
24hโ
7dโ
14dโ
30dโ
ytdโ
1yโ
๐ฆMarket Cap
$1.02B
Small Cap
๐Revenue Growth (YoY)
0.0%
Slowing
๐Gross Margin
0.0%
Thin
๐ตFCF Margin
0.0%
Thin
โ๏ธP/S Ratio
0.0x
Cheap
Otter Score
โ
Insufficient data
No chart data available for SGP.
Trading Snapshot
- Day Range
- โ
- 52-Week Range
- $17.06 โ $39.92
- Volume (shares)
- โ
- Avg Volume (shares)
- โ
- Shares Outstanding
- 33.5M
- Next Earnings
- 2027-03-25
Fundamentals Snapshot
- Annual Revenue
- โ
- Last Q Revenue
- โ
- P/E Ratio
- -14.4
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-2.11
- Dividend Yield
- 0.00%
SPYGLASS PHARMA INC
SGPFinancial Trends
Financial history unavailable.
About SPYGLASS PHARMA INC
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.
๐ฆฆ
Otter Score Breakdown
How it's scoredFive components, each rated 1โ5โ and equally weighted (20%), averaged to a 0โ100 score:๐ Quality โ gross margin๐ Growth โ revenue YoYโ๏ธ Valuation โ P/S ratioโก Momentum โ 30-day price change๐ง Dilution โ 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
๐Qualityโ
โ
โ
โ
โ
๐Growthโ
โ
โ
โ
โ
โ๏ธValuationโ
โ
โ
โ
โ
โกMomentumโ
โ
โ
โ
โ
Overall Score
Insufficient data
โ/100
Analyst data unavailable.
Latest News & Updates
News unavailable.